Overall, our study identifies, for the first time, c-JUN as a targetable mechanism of adaptive resistance to BRAF inhibition in BRAFV600E CRC paving the way to the development of future combinational therapeutic strategies incorporating JNKi. The gene discussed is JUN; the disease is colorectal carcinoma.